Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast.

Slides:

Advertisements

Similar presentations

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Hyaluronan and the Interaction Between CD44 and Epidermal.

Advertisements

Integrin-EGFR Cross-Activation Elizabeth Brooks Department of Chemical Engineering University of Massachusetts, Amherst Peyton Lab Group Meeting December.

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells by Toshihiko Tanno, Yiting Lim, Qiuju.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Reduction of Sca-1 increases PPARγ expression.

Volume 116, Issue 5, Pages (May 1999)

NRP2 represses IGF-IR expression and signaling.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

FAS1 domain protein inhibits association of αvβ3 integrin with VEGFR-2 and attenuates VEGF165-induced VEGFR-2 phosphorylation. FAS1 domain protein inhibits.

miR-335 targeted RANKL and reduced osteoclast induction in SBC-5.

NF1 downregulation activates MAPK pathway signaling.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

COX-2–PGE2 signaling is required for MSC-induced increase in ALDHhigh CSC-enriched population and tumor initiation. COX-2–PGE2 signaling is required for.

Chi-Hyun Park, Youngji Moon, Chung Min Shin, Jin Ho Chung

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

The selective PI3K inhibitor A66 suppresses PIP3 accumulation, AKT phosphorylation at Thr308, and YAP/TAZ–regulated gene expression in PDAC cells. The.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Transfection of stable β-catenin (S33Y) increased nuclear β-catenin and phosphorylated Akt expression (A) and reduced the promoting effect of HG on caspase-3.

PERK signaling is constitutively activated upon EMT and promotes malignancy. PERK signaling is constitutively activated upon EMT and promotes malignancy.

CEP55 is a downstream effector of MAPK signaling

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

P38 activation mediates chronic insulin-induced IRS1 and IRS2 degradation and is involved in myocardial insulin resistance in vitro. p38 activation mediates.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.

eNOS regulated IR-induced NO generation and EGFR signal activation.

Aggregation and toxicity of α-synuclein in HEK293T cells.

Oncogenic Ras signaling activates SFKs and promotes CDCP1-dependent invasion in 3-dimensional (3D) collagen raft culture of HCK. A, HCK1T-E cells, HCK1T-E.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

Induction of CDCP1 is regulated by Ras in NSCLC cells.

The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

Expression of versican G3 domain enhanced breast cancer cell mammosphere formation. Expression of versican G3 domain enhanced breast cancer cell mammosphere.

Protein expression profile in a dasatinib-resistant cell line.

DNA damage signaling regulates mutant p53 ubiquitination.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

ALDH1A3 is mainly responsible for the ALDH activity in two human cholangiocarcinoma lines. ALDH1A3 is mainly responsible for the ALDH activity in two human.

Mcl-1 knockdown promotes cleavage of caspase-3 in nonadherent melanoma cells. Mcl-1 knockdown promotes cleavage of caspase-3 in nonadherent melanoma cells.

A, GP and GR epithelial tumor cells are equally responsive to gefitinib. A, GP and GR epithelial tumor cells are equally responsive to gefitinib. Equal.

Expression of versican in mammary tumor stem/progenitor cells.

Sensor siRNAs can be used in high-order combinations.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

The expression of d-GM3 facilitates melanoma cell migration and invasion by activating p38 MAPK, not ERK. A, cell migration and invasion in d-GM3–positive.

MSP-T2 enhances metastatic ability of U87 cells.

Overexpression of L1 in CRC cells induces NF-κB activation and suppression of p65 expression blocks the capacity to confer liver metastasis. Overexpression.

Expression of CRC stem cell markers and L1 in CRC cells.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

PPP2R2A overexpression rescues the miR-21–induced biological effects in bladder cancer cells. PPP2R2A overexpression rescues the miR-21–induced biological.

The AKT–mTOR pathway controls PD-L1 protein expression.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

CDCP1 links Ras and SFK signaling and regulates anoikis resistance, cell migration, and invasion in NSCLC cells. CDCP1 links Ras and SFK signaling and.

GR CAFs modulate the EGFR-TKI response in cocultured tumor cells.

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

Changes in signal transduction pathway induced by gefitinib.

Expression of versican promoted breast cancer cell tumor formation and self-renewal in vivo. Expression of versican promoted breast cancer cell tumor formation.

EGFR signaling regulates transcription of PDGFRβ gene.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

AKT activation in HCC2429 is SRC- but not Notch-dependent.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.

T3 or T4 induces MAPK activation in myeloma cells.

Mechanism of ERM protein–dependent CD44 cleavage.

Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced proliferation in HepG2 cells. Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced.

Expression of anti-versican shRNA decreased breast cancer cell mammosphere and colony formation. Expression of anti-versican shRNA decreased breast cancer.

Loss of NQO1 expression inhibits invasion of NSCLC

AXL is not necessary for maintenance of intrinsic resistance.

Presentation transcript:

Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. A, numbers of mammospheres of G3-transfected 4T07 cells cultured in suspension with serum-free medium with or without EGF or with selective EGFR inhibitor AG1478 (2 μmol/L), selective MEK inhibitor PD 98059 (50 μmol/L), selective JNK inhibitor side population (SP) 600125 (100 nmol/L), or selective AKT inhibitor triciribine (2 μmol/L) for 14 days. The vector cells were also cultured in suspension with serum-free medium. Compared with G3 control cells; *, P < 0.05; **, P < 0.01; n = 3; analyzed with t test. B, all the suspended cells were cultured for 2 days, lysised, and subjected to immunoblotting with antibodies to pEGFR, pERK, GSK-3β (S9P), Sca-1, Sox2, ALDH1, and β-actin. C, the effects of expression of versican on breast cancer cell invasion, metastasis, and tumorigenesis via EGFR signaling. Overexpression of versican in breast caner cells enhances expression of pEGFR and its down-pathway pERK, pAKT. Expression of ERK enhances tumor cell migration, invasion, growth, and metastasis. Expression of pAKT enhances GSK-3β (S9P), and some stem cell markers—Sca-1, Sox2, ALDH1, resulting in tumor cell enhanced chemical resistance, cell survival, and cell self-renewal. D, the vector- and G3-transfected 4T07 cells were cultured in 10%FBS/DMEM with 40 μmol/L c2-ceramide or 2 μmol/L docetaxel for 24 hours, lysised, and subjected to immunoblotting with antibodies to GSK-3β (S9P), Sca-1, Sox2, ALDH1, and β-actin. William Weidong Du et al. Mol Cancer Res 2013;11:443-455 ©2013 by American Association for Cancer Research